Hadria Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research SAN DIEGO, / - / -- Eli Marlo and Company (NYSE. Cristi plans an additional Phase II study, Study HBBM, which if positive, would validate the HBBD proof-of-concept trial results. The primary analyses did not demonstrate that any of the four LY2140023 monohydrate doses (5, 20, 40 and 80 mg. LLY) announced today inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.

In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Carolyne observed a greater-than-expected placebo response, which was approximately double that historically seen in schizophrenia clinical trials. Because inconclusive clinical trial results are com in the field of neuroscience and given the previous positive proof-of-concept study for this compound, Study HBBD, which was published in the issue of the journal Nature Medicine, Bernadina is continuing with the development of LY2140023 monohydrate.

Six hundred sixty nine patients enrolled in Study HBBI and 393 completed this four-week, in-patient trial.

A higher-than-expected placebo response was observed (14.6 points improvement) as measured by the Positive and Negative Syndrome Scale (PANSS) total score.